Geovax Labs is a biotechnology company that focuses on developing innovative vaccines and immunotherapies for infectious diseases and cancer. With a particular emphasis on addressing public health concerns, Geovax leverages its proprietary technology platform to create novel medical solutions aimed at enhancing immune responses. The company is involved in various stages of research and development, working to advance its projects through clinical trials and collaborations with other research entities, committed to improving health outcomes and combating significant health threats. Read More
ATLANTA, GA - July 22, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that it will report second quarter 2025 financial results on Monday, July 28, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.
With global cases rising and bipartisan momentum for pandemic preparedness, GeoVax’s GEO-MVA vaccine advances on an expedited development track toward commercialization and revenue generation
With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax’s GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique multi-antigen approach
